June 2nd- LIVE from #ASCO26- Philadelphia-Positive ALL: The End of Chemotherapy and the Beginning of a New Era? CME Congresses . June 2nd- LIVE from #ASCO26- Philadelphia-Positive ALL: The End of Chemotherapy and the Beginning of a New Era? June 1st- LIVE from #ASCO26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL? CME Congresses . June 1st- LIVE from #ASCO26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL? May 31st- ASCO 2026: Teclistamab Changes the Rules at First Relapse — The Practice-Changing MajesTEC-9 Trial CME Congresses . May 31st- LIVE from #ASCO26- Teclistamab Changes the Rules at First Relapse — The Practice-Changing MajesTEC-9 Trial May 31st- SUCCESSOR-2: Has Mezigdomide Just Redefined Relapse Therapy in Multiple Myeloma? CME Congresses . May 31st- LIVE from #ASCO26- SUCCESSOR-2: Has Mezigdomide Just Redefined Relapse Therapy in Multiple Myeloma? May 29th- Beyond the Webinar: Can We Finally Modify the Natural History of Myelofibrosis? CME Congresses . May 29th- Beyond the Webinar: Can We Finally Modify the Natural History of Myelofibrosis? May 27th- CAR-T Before It’s Too Late: The New Myeloma Revolution CME Congresses . May 27th- CAR-T Before It’s Too Late: The New Myeloma Revolution May 25th- Dr. Satoshi Yamasaki- GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study CME Congresses . May 25th- Dr. Satoshi Yamasaki- GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study May 21st- From Dysbiosis to Therapeutics: The New Era of Microbiota in Allo-HCT CME Congresses . May 21st- From Dysbiosis to Therapeutics: The New Era of Microbiota in Allo-HCT May 18th- Can Peripheral Blood Replace Bone Marrow for MRD Monitoring in Myeloma? CME Congresses . May 18th- Can Peripheral Blood Replace Bone Marrow for MRD Monitoring in Myeloma? May 11th- Beyond the webinar: ISKIA and the New Era of MRD-Driven Myeloma Therapy: Are We Moving Closer to Cure? CME Congresses . May 11th- Beyond the webinar: ISKIA and the New Era of MRD-Driven Myeloma Therapy: Are We Moving Closer to Cure? Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23
